Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00205608
Status:
COMPLETED
Last Update Posted:
2010-06-28
First Post:
2005-09-13
Brief Title:
Microglia Activation in Schizophrenia
Sponsor:
Amsterdam UMC location VUmc
Organization:
Amsterdam UMC location VUmc
Study Overview
Official Title:
Microglia Activation in Schizophrenia a Pilot Study
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with schizophrenia have volume loss in gray matter This study is designed to evaluate whether their is microglia activation in schizophrenia using 11CR-PK11195 PET
Detailed Description:
Schizophrenia is a complex and chronic disease that affects different aspects of cognition and behaviour including attention perception thought processes emotion and volition Schizophrenia is a brain disease particularly involving decrement in gray matter as has been supported by findings from many imaging studies The pathophysiology of these gray matter changes has not been clarified Microglia activation is the consequence of virtually all conditions associated with neuronal injury When activated following neuronal damage microglia show a marked increase in the expression of peripheral type benzodiazepine binding sites which are particularly abundant on cells of the mononuclear macrophage
R-PK11195 1-2-chlorophenyl-N-methyl-N-11-methylpropyl-3 isoquinolinecarboxamide is a highly selective ligand for the peripheral benzodiazepine binding site R-PK11195 labelled with the positron emitter carbon-11 can be used to monitor the peripheral type benzodiazepine receptors using Positron Emission Tomography PET At the Vrije Universiteit Medical Centre R-11CPK11195 is used for studying microglia activation in-vivo in patients with traumatic brain damage minimal cognitive impairment and Alzheimer disease
The objective of this study is to determine whether and to what extent microglia activation occurs in schizophrenia Ten patients with schizophrenia will be recruited and 10 controls matched for age and gender This is an open study The study consists of one PET scan which will be performed at the Clinical PET Centre of the Vrije Universiteit Medical Centre All subjects will also get a MRI scan which will be performed at the department of Radiology University Medical Centre Utrecht
R-PK11195 1-2-chlorophenyl-N-methyl-N-11-methylpropyl-3 isoquinolinecarboxamide is a highly selective ligand for the peripheral benzodiazepine binding site R-PK11195 labelled with the positron emitter carbon-11 can be used to monitor the peripheral type benzodiazepine receptors using Positron Emission Tomography PET At the Vrije Universiteit Medical Centre R-11CPK11195 is used for studying microglia activation in-vivo in patients with traumatic brain damage minimal cognitive impairment and Alzheimer disease
The objective of this study is to determine whether and to what extent microglia activation occurs in schizophrenia Ten patients with schizophrenia will be recruited and 10 controls matched for age and gender This is an open study The study consists of one PET scan which will be performed at the Clinical PET Centre of the Vrije Universiteit Medical Centre All subjects will also get a MRI scan which will be performed at the department of Radiology University Medical Centre Utrecht
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None